文献速递肾小球疾病遗传性与小管间质肾病

MYO9A 被鉴定为单基因局灶节段性肾小球硬化的新候选基因

Rho-GTPase Activating Protein myosin MYO9A identified as a novel candidate gene for monogenic focal segmental glomerulosclerosis.
PubMed 文献 · Kidney Int · 2021-01-04

该研究在一对家族性 FSGS/蛋白尿同胞中描述了一个罕见的 MYO9A 功能缺失无义杂合突变(p.Arg701∗),并在 94 例经活检证实的 FSGS 患者中通过全外显子测序发现 MYO9A 意义不明变异。Myo9A 在小鼠和人足细胞中表达,敲入 p.Arg701∗ 的小鼠出现蛋白尿、足细胞足突消失和 FSGS,提示杂合功能缺失 MYO9A 突变可能引起新型人类常染色体显性 FSGS。

要点

  • MYO9A 是足细胞细胞骨架新组分,通过 Rho-GAP 域调节 RhoA 活性。
  • Myo9AR701X/+ 敲入小鼠重现先证者 FSGS 表型。
  • 需在更多家族性或散发性 FSGS 患者中鉴定 MYO9A 致病变异。

核心结论

  • Myo9A 是调节 RhoA 活性和足细胞功能的新型足细胞细胞骨架组分。
  • Myo9AR701X/+ 敲入小鼠重现先证者 FSGS 表型,证明 p.R701X Myo9A 是小鼠 FSGS 致病突变。
  • 杂合功能缺失 MYO9A 突变可能引起新型人类常染色体显性 FSGS。

研究设计与样本

  • 在家族性 FSGS/蛋白尿同胞对中发现罕见 MYO9A 功能缺失无义杂合突变(p.Arg701∗)。
  • 对 94 例经活检证实的 FSGS 患者行全外显子测序,发现 MYO9A 意义不明变异。
  • 通过基因编辑构建携带 p.Arg701∗MYO9A 的敲入小鼠(Myo9AR701X)。

主要发现

  • Myo9A 在小鼠和人足细胞体外和体内检测到。
  • Myo9AR701X 敲入小鼠出现蛋白尿、足细胞足突消失和 FSGS。
  • Myo9AR701X/+ 突变小鼠肾脏和足细胞显示 Myo9A 单倍剂量不足、RhoA 活性增加、Myo9A-肌动蛋白-钙调蛋白相互作用减少、足细胞附着和迁移受损。

临床怎么用

  • 对家族性或散发性 FSGS 患者可考虑 MYO9A 基因检测,尤其当怀疑常染色体显性遗传时。
  • 发现 MYO9A 功能缺失变异时,需结合家系共分离和功能证据评估致病性。

局限性

  • 需在更多家族性或散发性 FSGS 患者中鉴定 MYO9A 致病变异以确定该基因对疾病的贡献。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Focal segmental glomerulosclerosis (FSGS) is a podocytopathy leading to kidney failure, whose molecular cause frequently remains unresolved. Here, we describe a rare MYO9A loss of function nonsense heterozygous mutation (p.Arg701∗) as a possible contributor to disease in a sibling pair with familial FSGS/proteinuria. MYO9A variants of uncertain significance were identified by whole exome sequencing in a cohort of 94 biopsy proven patients with FSGS. MYO9A is an unconventional myosin with a Rho-GAP domain that controls epithelial cell junction assembly, crosslinks and bundles actin and deactivates the small GTPase protein encoded by the RHOA gene. RhoA activity is associated with cytoskeleton regulation of actin stress fiber formation and actomyosin contractility. Myo9A was detected in mouse and human podocytes in vitro and in vivo. Knockin mice carrying the p.Arg701∗MYO9A (Myo9AR701X) generated by gene editing developed proteinuria, podocyte effacement and FSGS. Kidneys and podocytes from Myo9AR701X/+ mutant mice revealed Myo9A haploinsufficiency, increased RhoA activity, decreased Myo9A-actin-calmodulin interaction, impaired podocyte attachment and migration. Our results indicate that Myo9A is a novel component of the podocyte cytoskeletal apparatus that regulates RhoA activity and podocyte function. Thus, Myo9AR701X/+ knock-in mice recapitulate the proband FSGS phenotype, demonstrate that p.R701X Myo9A is an FSGS-causing mutation in mice and suggest that heterozygous loss-of-function MYO9A mutations may cause a novel form of human autosomal dominant FSGS. Hence, identification of MYO9A pathogenic variants in additional individuals with familial or sporadic FSGS is needed to ascertain the gene contribution to disease.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Li Q, Gulati A, Lemaire M, et al. Rho-GTPase Activating Protein myosin MYO9A identified as a novel candidate gene for monogenic focal segmental glomerulosclerosis. Kidney Int. 2021. PMID: 33412162. doi:10.1016/j.kint.2020.12.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。